MedTrace Logo

HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

NCT04149743 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2024-08-21

No results posted yet for this study

Summary

Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.

Conditions

  • Heart Failure (HF)

Interventions

DIAGNOSTIC_TEST

Standard of Care with Hemotag

Comparison of outcomes

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Cleveland Clinic Florida

    collaborator OTHER

  • Aventusoft, LLC.

    lead INDUSTRY

Principal Investigators

  • David Snipelisky, MD · Cleveland Clinic Florida

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04149743 on ClinicalTrials.gov